开云app官网登录入口网页版-官方正版

#nemolizumab#

5篇内容 | 1241人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2218759, encodeId=5daa2218e5954, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a> <a href='/topic/show?id=e9846644229' target=_blank style='color:#2F92EE;'>#湿疹#</a> <a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a> <a href='/topic/show?id=f3541263873' target=_blank style='color:#2F92EE;'>#nemolizumab#</a>, objectTitle=《柳叶刀》：1周见效，四成患者症状减轻75%以上！创新湿疹疗法显著改善皮损和瘙痒, objectType=article, longId=837627, objectId=dfe783e627c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240525/1716651988616_92910.png, objectUrl=/article/show_article.do?id=dfe783e627c7, replyNumber=0, likeNumber=50, createdTime=2024-08-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=dfe783e627c7, moduleTitle=《柳叶刀》：1周见效，四成患者症状减轻75%以上！创新湿疹疗法显著改善皮损和瘙痒, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dfe783e627c7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194043, encodeId=e798219404379, content=<a href='/topic/show?id=23451124317d' target=_blank style='color:#2F92EE;'>#结节性痒疹#</a> <a href='/topic/show?id=1a26112140ef' target=_blank style='color:#2F92EE;'>#AAD 2024#</a> <a href='/topic/show?id=f3541263873' target=_blank style='color:#2F92EE;'>#nemolizumab#</a>, objectTitle=AAD 2024：结节性痒疹： Nemolizumab疗效持续52周的扩展研究, objectType=article, longId=817438, objectId=819381e43845, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240310/1710083397810_8624274.png, objectUrl=/article/show_article.do?id=819381e43845, replyNumber=0, likeNumber=65, createdTime=2024-03-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=819381e43845, moduleTitle=AAD 2024：结节性痒疹： Nemolizumab疗效持续52周的扩展研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=819381e43845)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2119036, encodeId=1fd82119036c3, content=抗-IL31受体α亚单位抗体<a href='/topic/show?id=f3541263873' target=_blank style='color:#2F92EE;'>#nemolizumab#</a>可缓解<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>AD患者的<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>，<a href='/topic/show?id=3b8a105643c7' target=_blank style='color:#2F92EE;'>#异硫*酸苯乙酯#</a>(PEITC)和<a href='/topic/show?id=33418810501' target=_blank style='color:#2F92EE;'>#萝卜硫素#</a>(SFN)也有这样的作用！, objectTitle=Pharmacol Res Perspect：异硫氰酸酯的止痒作用：Toll样受体3信号转导途径的潜在参与, objectType=article, longId=752968, objectId=840de5296863, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668018861856_4754896.png, objectUrl=/article/show_article.do?id=840de5296863, replyNumber=0, likeNumber=108, createdTime=2023-03-12, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=840de5296863, moduleTitle=Pharmacol Res Perspect：异硫氰酸酯的止痒作用：Toll样受体3信号转导途径的潜在参与, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=840de5296863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656488, encodeId=a8c9165648873, content=<a href='/topic/show?id=f3541263873' target=_blank style='color:#2F92EE;'>#nemolizumab#</a>, objectTitle=NEJM：皮下注射Nemolizumab治疗特应性皮炎瘙痒, objectType=article, longId=197293, objectId=abf119e29367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abf119e29367, replyNumber=0, likeNumber=60, createdTime=2021-04-08, rootId=0, userName=sunylz, userId=3e3924864061, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abf119e29367, moduleTitle=NEJM：皮下注射Nemolizumab治疗特应性皮炎瘙痒, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=abf119e29367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656486, encodeId=912a165648698, content=<a href='/topic/show?id=f3541263873' target=_blank style='color:#2F92EE;'>#nemolizumab#</a>, objectTitle=NEJM：Nemolizumab对中度至重度结节性瘙痒患者的疗效, objectType=article, longId=188477, objectId=e1921884e7f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1921884e7f6, replyNumber=0, likeNumber=65, createdTime=2020-05-21, rootId=0, userName=sunylz, userId=3e3924864061, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1921884e7f6, moduleTitle=NEJM：Nemolizumab对中度至重度结节性瘙痒患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e1921884e7f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656487, encodeId=f5c4165648e15, content=<a href='/topic/show?id=f3541263873' target=_blank style='color:#2F92EE;'>#nemolizumab#</a>, objectTitle=NEJM：nemolizumab治疗中重度结节性瘙痒的II期临床取得积极结果, objectType=article, longId=188515, objectId=c1f8188515d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1f8188515d5, replyNumber=0, likeNumber=72, createdTime=2020-09-13, rootId=0, userName=sunylz, userId=3e3924864061, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1f8188515d5, moduleTitle=NEJM：nemolizumab治疗中重度结节性瘙痒的II期临床取得积极结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c1f8188515d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656485, encodeId=2caf1656485d7, content=<a href='/topic/show?id=f3541263873' target=_blank style='color:#2F92EE;'>#nemolizumab#</a>, objectTitle=NEJM: nemolizumab对特应性皮炎的治疗效果, objectType=article, longId=90921, objectId=fbfb9092167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbfb9092167, replyNumber=0, likeNumber=85, createdTime=2018-01-26, rootId=0, userName=sunylz, userId=3e3924864061, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbfb9092167, moduleTitle=NEJM: nemolizumab对特应性皮炎的治疗效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fbfb9092167)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

nemolizumab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#局部治疗# #湿疹# #特应性皮炎# #nemolizumab#

《柳叶刀》：1周见效，四成患者症状减轻75%以上！创新湿疹疗法显著改善皮损和瘙痒

2024-08-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#结节性痒疹# #AAD 2024# #nemolizumab#

AAD 2024：结节性痒疹： Nemolizumab疗效持续52周的扩展研究

2024-03-19发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

抗-IL31受体α亚单位抗体#nemolizumab#可缓解#特异性皮炎#AD患者的#瘙痒#，#异硫*酸苯乙酯#(PEITC)和#萝卜硫素#(SFN)也有这样的作用！

Pharmacol Res Perspect：异硫氰酸酯的止痒作用：Toll样受体3信号转导途径的潜在参与

2023-03-12发表于上海

sunylz (审核中...)

前往app查看评论内容

#nemolizumab#

NEJM：皮下注射Nemolizumab治疗特应性皮炎瘙痒

2021-04-08

sunylz (审核中...)

前往app查看评论内容

#nemolizumab#

NEJM：Nemolizumab对中度至重度结节性瘙痒患者的疗效

2020-05-21

sunylz (审核中...)

前往app查看评论内容

#nemolizumab#

NEJM：nemolizumab治疗中重度结节性瘙痒的II期临床取得积极结果

2020-09-13

sunylz (审核中...)

前往app查看评论内容

#nemolizumab#

NEJM: nemolizumab对特应性皮炎的治疗效果

2018-01-26

科室
- - 订阅+
  - 更多科室
工具
服务